Long bone and in particular tibia fractures frequently fail to heal. A disturbed revascularisation is supposed to be a major cause for impaired bone healing or the development of non-unions. We aim to establish an animal model, which reliably mimics the clinical situation. Human microvascular endothelial cells (HMEC-1) and primary human osteoblast like cells (POBs) were cultured with different angiogenesis-inhibitors (Fumagillin, SU5416, Artesunate and 3,5,4'-Trimethoxystilbene) released out of poly(D,L-Lactide) (PDLLA) coated k-wires and cell activity was determined. Discs containing PDLLA or PDLLA + Fumagillin/Artesunate were placed at the chorionallantoic membrane of hen eggs and the effect on vessel formation and egg vitality was observed. Tibia osteotomy was performed in rats and stabilised with K-wires coated with PDLLA + Fumagillin or with PDLLA only (control group). The healing was compared at different time points to the PDLLA control. Fumagillin and Artesunate inhibited the activity of HMEC-1 with minor effect on POBs. Artesunate caused embryonic death, whereas Fumagillin had no effects on egg vitality, but reduced the blood vessels. In the animal study all rats showed an impaired healing with reduced biomechanical stability. The Fumagillin treated tibiae had a signifi cantly decreased radiographic callus size at day 42 and 84, less blood vessels in the early callus, a reduced histological callus size at day 10, 28 and 84, as well as an altered callus composition. This study presents a less vascularised, atrophic, tibia non-union and can be used in further investigations to analyse the pathology of atrophic non-union and to test new interventions.
Introduction
Despite recent improvements in surgical methods, fracture healing, especially of long bones, is still accompanied by severe complications. Tibia fractures are reportedly the most common long bone lesions and have the highest non-union rate ranging from 1 % to 80 % depending on the anatomical localisation and the severity of the trauma (Tzioupis and Giannoudis, 2007) . Weber described a scoring system, which is based on the radiographic appraisal of non-unions (Weber, 1982) . According to this classifi cation, non-unions are separated in different vital and avital forms. Hypertrophic non-unions are considered to be biologically active and vascularised whereas atrophic non-unions are considered to be relatively biologically inactive and more or less avascular. But, patients with nonunions are rarely easily compared and it is now known, that more precise classifi cation systems with respect to the individual situation of the patient are needed . Contradictory fi ndings about the vascularity at the lesion site in case of healing failure had been made. Signifi cantly higher non-union rate and a greater number of weeks to union were observed in fractures associated with an injury to the posterior tibial artery than in fractures without this vascular injury (Brinker and Bailey, 1997) . In contrast to this a further study was not able to confi rm a difference in vessel density comparing biopsies taken from the fracture gap of patients who developed a hypertrophic or an atrophic non-union or from patients who showed a regular healing pattern . Despite this debate about the defi nition of non-unions, it is currently assured that vascularisation plays an important role in fracture healing interactions . Both pathways, the angiogenic and the osteogenic, are intimately linked and are sharing molecular key factors e.g. the vascular endothelial growth factor or the bone morphogenetic proteins (Deckers et al. 2002; Dai et al., 2007; Beamer et al., 2009) . But, it is not understood why some patients do develop a non-union and some patients do not and which endogenous factors are miss-regulated in these patients. Inhibitors of angiogenesis are clinically used in cancer therapy and other diseases (Folkman, 2004; Sivakumar et al., 2004; Folkman, 2007) . One of the most potent antiangiogenic agents is Fumagillin, a naturally secreted antibiotic of the fungus Aspergillus fumigatus (Ingber et al., 1990) . Fumagillin inhibits the methionineaminopeptidase type II through covalent binding (Sin et al., 1997; Liu et al., 1998) , which leads more downstream to a block of the noncanonical Wnt-signalling pathway (Zhang et al., 2006). SU5416 [3-(3,5- inhibitor of the vascular endothelial growth factor (VEGF)-receptor 2 tyrosine kinase. It inhibits VEGF-dependent endothelial cell proliferation in vitro and in vivo (Ye et al., 2006) and was the fi rst VEGF-receptor 2 inhibitor to enter clinical development. Artesunate, a derivative of Artemisinin, has a long tradition in the treatment of fever and malaria (Klayman, 1985) , but also possess antitumor activity and antiangiogenic potential (Efferth et al., 2003; Chen et al., 2004; Dell´Eva et al., 2004) by lowering VEGF and VEGF-receptor expression (Chen et al., 2004; Zhou et al., 2007) . 3,5,4´-Trimethoxystilbene is a herbal antioxidant present in high concentrations in red wine (Frémont, 2000; Belleri et al., 2005) . This factor acts through down regulation of VEGF-receptor 2 and cellcycle modulation (Alex et al., 2010) causing microtubule disorganization in vitro as well as inhibition of blood vessel growth in ovo and in vivo (Belleri et al., 2005) . A disturbed revascularisation after bone lesion has been so far created in different animal models by intensive mechanical interference, e.g. destruction of the periosteum, endosteum or the medullary canal or a combination of these techniques (Triffi t et al., 1993; Hietaniemi et al., 1995; or an induction of a unilateral total hind limb ischemia (Lu et al., 2007) . One study applied systemically a synthetic Fumagillin analogue (TNP-470) in a rat femur fracture model, but they did not analyse the effect on revascularisation (Hausman et al., 2001) . Until there is no causal clinical therapy for the treatment of nonunions available, reliable animal models, which mimic the clinical situation and investigate the role of blood supply after bone trauma, are essential. In this study we aimed fi rstly to select a substance which inhibits selectively endothelial proliferation without having an impact on bone forming cells. For this purpose in vitro experiments were performed to test the infl uences of Fumagillin, SU5416, Artesunate and 3,5,4´-Trimethoxystilbene on endothelial cells and osteoblast like cells and on the vascularisation in an in-ovo model. Further on, the selected substance was tested in vivo after tibia osteotomy. For this purpose we used an impaired healing model, which had already been established by our group (Kratzel et al., 2008) as control. Bone healing parameters were compared between the PDLLA control group (tibia osteotomy and stabilisation with inhibitor-free PDLLA coated wires) and the treatment group (tibia osteotomy and stabilisation with PDLLA/ inhibitor coated wires).
LOCAL INHIBITION OF ANGIOGENESIS RESULTS IN AN ATROPHIC NON-UNION IN A RAT OSTEOTOMY MODEL

Material and Methods
Polymer coating of titanium kirschner-wires (k-wires) We used the polymer poly(D,L-Lactide) (PDLLA) (Boehringer Ingelheim, Ingelheim, Germany), for incorporating substances. The release of factors from this coating showed an initial burst release within the fi rst 2 days followed by a sustained release over the following 40 days (Schmidmaier et al., 2001) . PDLLA was dissolved in ethyl acetate (100 mg in 1. , 1985) . The cells were cultured at 37 °C, 5 % CO 2 , and 95 % humidity in MEME/F12 1:1 + 10 % foetal calf serum (FCS) + 1 % penicillin/streptomycin (PS), + 0.05 mM L-ascorbate-2-Phosphate, + 0.05 mM ß-glycerolPhosphate (Biochrom) (POB), or MCDB 131 media (Invitrogen, Darmstadt, Germany) + 2 mM L-Glutamine, 5 % FCS, 1 % PS (Biochrom) + freshly supplemented 1 μg/mL hydrocortisone (Sigma-Aldrich) (HMEC-1), respectively. We seeded the cells in 96-well plates (5 x 10 3 vital cells/ well/100 μL of HMEC-1 and 1 x 10 3 vital cells/well/100 μL of POBs). After 3 h (HMEC-1) or overnight incubation (POBs), Alamar Blue (Biozol, Eching, Germany) (1:10 in media) was added to measure metabolic cell activity. Optical density was measured after 3 h incubation (Microplate Reader; Bio-Rad Laboratories, München, Germany). Subsequently, coated kirschner-wires were added to the cells with fresh media and continued culturing. We repeated the Alamar Blue Assay after 3 and 6 d. The experiments were performed in quadruplicates and repeated twice.
Hen's egg chorioallantoic membrane test (HET-CAM Test)
Fertilised domestic chick embryos were incubated at 37 °C, 70 % humidity and periodic rotation. On day 6 a small hole was formed by carefully removing the shell membrane and the chorioallantoic membrane was photographed. A small round fi lter paper (approximately 5 mm in diameter) containing PDLLA and PDLLA with incorporated inhibitors Fumagillin or Artesunate (10 % w/w) was gently placed on the exposed area of the chorioallantoic membrane. The incubation was continued with the window upright for 30 h. After removing the eggs from the incubator, the chorioallantoic membrane M Fassbender et al. Angiogenesis and bone healing was photographed a second time. Egg vitality and blood vessel appearance was evaluated visually by three different observers regarding vessel formation.
Surgical model
All animal experiments were approved by the local authorities. Five month old female Sprague Dawley rats, weighing 250-280 g, were used. A detailed description of the surgery and some results of the PDLLA control group have already been published (Kratzel et al., 2008) . Briefl y, the medullar cavity of the tibia was opened and reamed twice. The tibia was osteotomised at the midshaft level using a diamond disk (HORICO, Berlin, Germany). For stabilisation a kirschner-wire coated with substance-free PDLLA (control) or 10 % w/w Fumagillin in PDLLA was inserted from the proximal end of the tibia into the medullar canal. The fi bula was fractured manually. The wound was closed and gentamycin ointment was applied locally. Euthanasia was performed in deep anaesthesia by an intracranial injection of potassium chloride. The former PDLLA control group was not re-operated, because we followed the 3-R principle (replace, reduce and refi ne) for animal testing, but the animals were operated by the same surgeon within 12 month. Healing outcomes were followed as stated in Table 1 .
Radiographic analysis
Radiographs were taken (46 KV/2.5 mAS; Kodak DirectView CR Cassette; Mobilett Plus X-ray unit Siemens AG, Erlangen, Germany) (posterior-anterior / lateromedial) after surgery and at day 5, 10, 28, 42 and 84 (Table 1) . The callus diameter proximally and distally adjacent to the osteotomy gap was analysed by one observer (MF) using Image-J Version 1.30 (National Institutes of Health, Bethesda, MD, USA). Each measurement was performed in both views and repeated three times. The mean coeffi cient of variance of repeated single measurements was 2.72 %. Mean values were calculated and callus diameter was expressed as a percentage to day 0.
Biomechanical testing
We performed biomechanical testing at day 42 and 84 (Table 1) as previously described (Kratzel et al., 2008) . For biomechanical testing, the tibiae were fi xed in a special device and preloaded with an axial force of 5 Newton. A constant linear propulsion (1 mm/min), generated by a material testing machine (Zwick 1455, Ulm, Germany), was applied to a lever arm attached to one of the pivoted axes for transforming the translation of the material-testing machine to a uniform torsional movement. The other side was connected with a load cell (Fmax = 50 N, HBM, Darmstadt, Germany) which recorded the force. Maximum load and torsional stiffness was calculated. The values were expressed as percentages of the contralateral intact tibia.
Histological analysis
For histological evaluation at days 5, 10, 28, 42 and 84 (Table 1) , the soft tissue was removed from the entire tibia taking care not to destroy the callus tissue. Bones were fi xed for 48 h in 10 % normal buffered formalin. Bone specimens taken at day 5 and 10 (n = 14 per time point) were decalcifi ed with Ethylenediaminetetraacetate (EDTA), dehydrated, embedded in paraffi n and longitudinal sections (4 μm; Leica SM 2500s microtome, Wetzlar, Germany) were made. Slices were stained with haematoxylin and eosin (HE). For visualisation of the vessels the paraffi n slices were rehydrated, blocked with normal horse serum (Vector Laboratories, Burlingame, CA, USA) and incubated with monoclonal mouse anti human smooth muscle actin (Dako, Glostrup, Denmark; Clone 1A4; dilution 1:100) for 1 h at 37 °C. Alkaline phosphatase anti-mouse antibody was used as secondary antibody (Vector Laboratories; AP-2000; dilution 1:200; 30 min incubation period at room temperature). Visualisation was done with the alkaline phosphatase substrate kit (Vector Laboratories). Day 28, 42 and 84 (n = 14 per time point) samples were transferred after formalin fixation into polymethylmethacrylate (Technovit 9100 neu; Heraeus Kulzer, Wehrheim, Germany). Ten longitudinal sections (4 μm) were cut and stained using Safranin-Orange/von Kossa (SafO/vK) and Safranin-Orange/Light green (SafO/ Lg). A region of interest (ROI) was defi ned, including the zone of reactive callus proximally and distally from the centre of the osteotomy gap extended in length 1.5-fold of the individual cortical bone diameter. Within this region, early reactive callus (HE), blood vessel density (α-SMA), amount of mineralised and nonmineralised tissue (SafO/vK), and cartilaginous tissue (SafO/Lg) was determined using a DM-RB microscope (Leica) and an image analysing system (KS 400; Zeiss, Göttingen, Germany) as described previously Kratzel et al., 2008) . Figs. 1, 3, 4 and 5) are presented as 50th percentile (median) and 75th percentile (top of each box) and 25th percentile (bottom of each box). The whiskers (the lines that extend out the top and bottom of the box) represented the highest and lowest values that were not outliers or extreme values. In Fig. 6 
Results
In vitro and in ovo effect of angiogenesis inhibitor
Fumagillin and Artesunate specifi cally inhibited endothelial cell proliferation with less affecting osteoblasts. The HMEC-1 treatment was associated with a significant inhibiting effect on metabolic cell activity except for Fumagillin at 5 %w/w and SU5416 at all concentrations at day 3 and 6. The POB treatment showed negative effects, too, but for Fumagillin at 5 %w/w at day 3 and 6 and at 10 %w/w at day 3, SU5416 at 5 %w/w at day 3, and Artesunate at 5 %w/w at day 3 and 6 differences in cell activity were not signifi cant (Fig. 1) . Based on the results of the cell culture experiments 10 %w/w of Fumagillin and Artesunate were investigated in the HET-CAM Test. The PDLLA control and Fumagillin had a minor infl uence on the egg vitality; whereas the application of Artesunate caused rapid embryonic death. The application of Fumagillin resulted in a reduced number of blood vessels and smaller capillaries disappeared after exposure (Fig. 2) . Therefore, an implant coating with 10 % Fumagillin was used in the animal experiments.
In vivo effect of Fumagillin on osteotomy healing
All outcome parameters assessed indicated a delayed healing in both groups and an atrophic non-union with altered callus composition in the Fumagillin treated group Signifi cant differences due to the drug treatment were seen when compared to the control group (*: day 3; **: day 6). (B) Primary human osteoblast like cells (POBs) at different time points of cultivation (after day 3 = light gray; after day 6 = dark gray) with different concentrations of the four different inhibitors (%w/w in PDLLA) compared to day 0 in percent.
Shown are for both tests the signifi cant differences after Bonferroni-Holm correction. (A) A signifi cant reduction of the metabolic activity of HMEC-1 was achieved by Trimethoxystilbene and Artesunate at 5, 10 and 20 % and Fumagillin at 20 %w/w of PDLLA (day 3 and 6, p < 0.0001) and Fumagillin at 10 %w/w of PDLLA (day 3, p = 0.0001; day 6, p = 0.004). (B) A signifi cant reduction of the metabolic activity of POBs was achieved by Trimethoxystilbene at 5, 10 and 20 % , Artesunate at 10 and 20 %, SU 5416 at 10 and 20 % (day 3 and 6, p < 0.007), SU 5416 at 5% (day 6, p = 0.0001) and Fumagillin at 20 % (day 3, p = 0.0005; day 6, p = 0.0003) and at 10 % w/w in PDLLA (day 6, p = 0.0029).
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compared to the untreated PDLLA control group. Beside one animal, which displayed osseous bridging of the tibial cortex in both views, in all other animals the osteotomy gap remained visible until day 84. The radiographic evaluation revealed a signifi cantly reduced callus diameter in the Fumagillin group at day 42 (p = 0.043) and day 84 (p = 0.011) [% to day 0] (Fig 3) . Maximum load and torsional stiffness showed no signifi cant differences between both groups and in all groups the median values were below 50 % compared to the intact tibiae, indicating no healing (Fig. 4) . The blood vessel counts resulted in a signifi cant reduced vessel density in the Fumagillin group compared to the PDLLA control (Fig. 5 ) at day 5 (p = 0.005) and day 10 (p = 0.001). In one animal with bone consolidation on the radiograph, bilateral mineralised callus tissue was seen in the histology. All other animals revealed cortical non-union and incomplete periosteal bridging until day 84 with remaining cartilage tissue. Regarding the early
Fig 4.
The columns show comparison of the biomechanical properties of the osteotomised tibiae (maximum load and torsional stiffness as % of contralateral intact tibiae). Number of analysed osteotomised tibiae: n = 6 (PDDLA control, 42 days), n = 7 (Fumagillin, 42 days), n = 5 (PDLLA control, 84 days) and n = 7 (Fumagillin, 84 days).
Fig. 5. These images (A, B, C)
are examples of blood vessels within the callus at day 5 (A, PDLLA control; B, Fumagillin group; C, negative control, without primary antibody). cb = cortical bone; ca = callus; α-smooth muscle actin (sma)-staining, scale bar: 100 μm. Vessel density differed signifi cantly between both groups at day 5 and 10 (C).
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time points, the evaluation of the total callus size in [mm 2 ] showed a reduced callus tissue formation in Fumagillin group compared to PDLLA control at day 5 (9.5 versus 17.7 versus, not signifi cant) and at day 10 (11.2 versus 24.3, p = 0.001). Regarding the late time points, the histomorphometry revealed a smaller total periosteal callus (mm²) in the Fumagillin group at day 28 (p = 0.019) and day 84 (p = 0.005) (Fig 5.) whereas the mineralised tissue fraction of the callus area (%) was higher in the Fumagillin than in the PDLLA control at day 42 (p = 0.001) (Fig. 6) .
Discussion
To our knowledge this is the fi rst study to demonstrate, that Fumagillin reduced the number of blood vessels in the early phase of bone healing and therefore inhibited angiogensis when locally delivered from a PDLLA implant coating after bone lesion. This is mainly important with regard to clinical aspects, because a disturbed blood supply is supposed to be a major cause of delayed union or non-union during fracture healing. It has been shown in previous work that the extent of vascular damage is correlated with failure of bone repair (Dickson et al., 1995; Einhorn, 1995; . For the better understanding of the underlying mechanisms and for the development of new therapy options, animal models, which come as close as possible to the clinical situation, are essential. In the present model the defect stabilisation with substance free PDLLA coated wires led to a delayed union with hypertrophic callus appearance, whereas the application of Fumagillin and the disturbance of revascularisation indicated the development of an atrophic non-union, and a reduced callus size and altered callus composition.
To identify a potent angiogenesis inhibitor and the right concentration we performed in vitro and in ovo experiments. The in vitro experiments, aside from SU5416, confi rmed the inhibitory action of Fumagillin, Artesunate, and 3,5,4´-Trimethoxystilbene on endothelial cells. A similar dose-dependent negative effect on the proliferation had been described recently in different types of endothelial cells (Wang et al., 2000; Chen et al., 2004; Dell`Eva et al., 2004; Hou et al., 2009; Alex et al., 2010) . The POB-like cells were less affected by adding either antiangiogenic substances. In accordance to that fi nding a selective mode of action has been proven for Fumagillin during in vitro co-culture of human endothelial and nonendothelial cells (Wang et al., 2000) . Based on the fact, that Trimethoxystilbene had a strong inhibiting effect on both cell types, HMEC-1 and POBs, at all concentrations Angiogenesis and bone healing and that SU5416 showed no signifi cant inhibiting infl uence on cell activity of HMEC-1, we continued with Fumagillin and Artesunate for the in ovo HET-CAM Test. Fumagillin not only reduced the formation of new vessels but also seemed to lead to a regression of already existing vessels. This is in accordance with a previously published study reporting a generally reduced vasculature without severe alteration of vessel organisation, a reduced artery and vein length as well as a shrinking of major vein and artery branches (Hazel, 2003) . Artesunate caused the death of chicken embryos in the present study. This was also seen by Zhou et al. demonstrating that higher concentrations structurally altered CAMs including cell degeneration and destroyed cell integrity as well infi ltration of infl ammatory cells (Zhou et al., 2007) . This lethal effect of Artesunate seen in the HET-CAM Test, however, will not occur in the adult rats. Based on the very low dosage and the single mode of application we would not expect, that the animals will be severely affected or die after the administration of Artesunate. But, in respect to the high survival rate of about 85 % of the chicken embryos after Fumagillin application, we decided to continue with the Fumagillin for the in vivo experiments.
To our knowledge there is only one study, which used a pharmaceutical approach to inhibit vascularisation during bone healing. Hausman et al. systemically applied the Fumagillin analogue TNP-470 after femur osteotomy in rats (Hausman et al., 2001) . In contrast to this, in the current study the antiangiogenic substance has been incorporated in the PDLLA-coating of k-wires, which were used for mechanical stabilisation. Local delivery patterns can achieve high concentrations of the active substances at the interface of implant and bone and coevally can minimise negative side effects which might be caused by systemically application. The PDLLA has been shown to be an appropriate coating for local release of various factors (Schmidmaier et al., 2001; Wildemann et al., 2004; Lucke et al., 2005; Pauly et al., 2009) . In contrast to the current study, Hausman et al. reported a total absence of callus in the radiographs, a mainly uniform appearing fi brous tissue with few chondrocyte-like cells and minimal woven bone in the histology in the fractured and Fumagillin treated group. Furthermore, they reported a signifi cant difference in the biomechanical properties between the fractured but untreated control and the fractured but treated group. The more pronounced differences in the biomechanical competence are explained by the regular healing pattern in the control. In the current study a delayed healing model was used for the control as well as for the treatment group and therefore we did not expected differences in the mechanical competence of the bones. In the study of Hausman et al. (2001) there were no remarks concerning the vascularity at the lesion side and therefore, the direct inhibiting effect of Fumagillin on angiogenesis was not proven. Other experimental models, that aim to investigate the vascularity of atrophic non-unions, have so far been created in rats and rabbits by severe mechanical manipulations (Triffi t et al., 1993; Bronlow et al., 2002; . Osteotomy in combination with destruction of the periosteum or endosteum and curettage of the intramedullary canal resulted in a significant reduction of blood vessels in the interfragmentary gap during the early post-operative phase and the subsequent development of non-unions. However, it is well accepted that the periost as well as the bone marrow provide various factors and cells, which are known to play a key role in bone repair. Therefore, in clinical situations, the protection of the periosteum is of high priority. With respect to this, we aimed to achieve the inhibition of neovascularisation after bone trauma using an alternative method.
An extreme model of disturbed vascularisation was used by Lu et al. (2007) by resection of the femoral artery in a mouse tibia fracture model. The ischemia resulted in an impaired bone healing with a decreased callus area including reduced callus and, in contrast to their expectations, reduced cartilage. In the present study however, the inhibition of angiogenesis caused a tendency towards a higher mineralised content with signifi cant differences at day 42. The cartilage area was slightly but not signifi cantly enlarged.
The last could be seen in accordance with the well accepted effect of hypoxia on the differentiation of bone marrow stem cells in the chondrogenic lineage (Kanichai et al., 2008) . Unlike the method applied by Lu et al. (2007) -which caused severe complications including toe, foot and hind limb necrosis as well as death -there were no indications of negative effects of Fumagillin on general health or gross perfusion of the lower leg in our study.
Further studies will be performed to investigate the healing over time using μCT to gain more information on the mineralisation of the callus, the callus formation and also the vascularisation at the later time points. Reed et al. established a rat atrophic non-union model using a 1 mm defect with cauterisation of the periost and endost . The investigation of the vascularisation revealed a reduced vessel number only at the early healing phase but not after 8 weeks. The group found similar results in a rabbit model . If the revascularisation is also impaired only in the early healing phase of the present atrophic non-union model, it must be evaluated in further studies. In addition, the callus remodelling will be investigated at the later time points with a special focus on osteoclast like cells. This important information is missing in the present study but is necessary for the description of the model.
In conclusion, we demonstrated that Fumagillin is a selective inhibitor of endothelial cell activity and reduces number of visible blood vessels in the chorioallantoic membrane of hen eggs. A reduction of early blood vessel number within the callus tissue can be achieved by local release. Our results indicated that angiogenesis inhibition has an impact on callus tissue formation and bone healing. We considered this model favourable to mimic the pathologic healing seen in human atrophic non-unions and to be suitable for effi cacy testing of newly developed therapeutic strategies. For testing new drugs the induced non-union must be debrided and the nail with the Fumagillin coating removed. After this, a nail coated M Fassbender et al. Angiogenesis and bone healing with a therapeutic drug can be inserted and the healing process monitored. Furthermore, this study can be used for continuing analysis of angiogenic and osteogenic factors. The present study describes a clinically relevant rat model, which shows the formation of an atrophic nonunion after 84 days. The inhibition of angiogenesis resulted in a reduced vessel formation in the early healing phase accompanied with a smaller callus at the later healing phase. This model allows for the investigation of the pathology and also new treatment strategies.
